| 30–50 % of all CPs | |
Age at presentation | Peak at 5–14 years1 | Peak at 40–44 years2 |
|
Gender distribution (m/f) | Equal8,21 | Equal8,27 |
|
Most frequent presentation | Headache (68–85%) | Visual impairment (40–84%) |
Visual impairment (36– 55%) | Menstrual irregularities (57%) |
Growth failure (7–36%)9,35,66 | Headache (42–56%)13,26,27 |
|
Pathohistological type | Adamantinomatous 99% | 33 |
Papillary extremely rare* | Papillary 14–50% |
|
Initial hypothalamic involvement | 42–66%8,9,35 | 42%18 |
|
Endocrine deficits at diagnosis | | |
|
Any | 40–87%8,13,21,35,65,66 | 41–73%8 |
GH | 41–75%8,13,21,35,65,66 | 18–86%8,13 |
FSH/LH | 20–56%8,13,21,35,65,66 | 29–74%8,13 |
ACTH | 8–68%8,13,21,35,65,66 | 35–58%8,13 |
TSH | 15–32%8,13,21,35,65,66 | 35–56%8,13 |
ADH | 7–17%8,13,21,35,65,66 | 6–17%8,13 |
|
Pituitary hormone deficiencies after treatment | | |
|
Any | 64–100%8,64 | 48–97%8,64 |
GH | 93–96%8,18,21 | 52–68%8,18 |
FSH/LH | 59–95%8,18,21 | 70–94%8,18 |
ACTH | 78–100%8,18,21 | 74–88%8,18 |
TSH | 86–100%8,18,21 | 81–92%8,18 |
ADH | 65–96%8,18,21 | 43–70%8,18 |
Panhypopituitarism*** | 43–100%8,18,64 | 59–74%8,18,64 |
|
Obesity** | 44–64%8,9,19,64 | 41–47%8,19,64 |